Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study

Loading...

Interactive visualization of Health-Related Quality of Life (HRQOL) outcomes from the MONALEESA-3 study.

Citation -

DOI -

Year -

Study Design & Arms

Comparison of Ribociclib + Fulvestrant vs. Placebo + Fulvestrant in HR+, HER2- advanced breast cancer.

Mean baseline scores (with Standard Deviation) for Global Health Status and Pain. Groups were well balanced.

Comparison of median time to 10% deterioration. Higher is better.

HR < 1 favors Ribociclib. Error bars represent 95% Confidence Intervals.

Select a metric to view detailed values and provenance.

Overview of outcomes. Green indicates favorable trend (HR < 1 or higher baseline score).

Metric ID	Metric Name	Group	Value	Source

Primary

Secondary

Accent

Card Bg

Text

Font

👀 View Mode